Finance

Lists
301333:SHE
R&G PharmaStudies Co Ltd
CNÂ¥60.20
+7.54%
(+4.22) 1D
Sep 8, 3:04:55 PM GMT+8  ·   CNY
All symbols
SymbolPriceChange% Change
Generating top insights for 301333...
Open
CNÂ¥56.11
High
CNÂ¥60.54
Low
CNÂ¥54.83
Mkt. cap
5.41B
Avg. vol.
3.59M
Volume
6.28M
Dividend
0.27%
Quarterly dividend
CNÂ¥0.04
Ex-dividend date
Jul 3, 2026
P/E ratio
48.17
52-wk high
CNÂ¥91.78
52-wk low
CNÂ¥43.79
EPS
CNÂ¥1.25
Shares outstanding
96.58M
No. of employees
3K
Open
CNÂ¥56.11
High
CNÂ¥60.54
Low
CNÂ¥54.83
Mkt. cap
5.41B
Avg. vol.
3.59M
Volume
6.28M
Dividend
0.27%
Quarterly dividend
CNÂ¥0.04
Ex-dividend date
Jul 3, 2026
P/E ratio
48.17
52-wk high
CNÂ¥91.78
52-wk low
CNÂ¥43.79
EPS
CNÂ¥1.25
Shares outstanding
96.58M
No. of employees
3K
About R&G PharmaStudies Co Ltd
CEO-
Employees2.64K
FoundedAug 22, 2008
Headquarters-
SectorHealth care
Previous reportsAll values in CNY
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in CNY
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
227.71M
243.64M
218.09M
249.87M
Cost of goods sold
153.16M
164.25M
152.25M
174.53M
Cost of revenue
153.16M
164.25M
152.25M
174.53M
Research and development expenses
15.10M
16.19M
15.51M
18.39M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
22.99M
30.78M
23.05M
24.60M
Operating expense
38.00M
50.32M
39.67M
43.34M
Total operating expenses
191.16M
214.57M
191.92M
217.87M
Operating income
36.55M
29.07M
26.18M
32.00M
Other non operating income
-1.56M
1.43M
-3.03M
-7.99M
EBT including unusual items
39.46M
45.33M
25.76M
24.43M
EBT excluding unusual items
40.16M
32.65M
26.20M
24.11M
Income tax expense
4.17M
3.87M
2.88M
1.95M
Effective tax rate
10.56%
8.54%
11.16%
7.97%
Other operating expenses
1.04M
1.05M
1.01M
438.25K
Net income
34.45M
41.33M
22.83M
21.64M
Net profit margin
15.13%
16.96%
10.47%
8.66%
Earnings per share
-
-
-
-
Interest and investment income
5.23M
6.24M
3.65M
605.42K
Interest expense
-623.53K
-623.36K
-605.42K
-506.12K
Net interest expenses
4.61M
5.62M
3.05M
99.30K
Depreciation and amortization charges
-
-
-
-
EBITDA
38.49M
30.77M
27.88M
37.28M
Gain or loss from assets sale
-
9.34K
-
-3.52K
AI content may include mistakes. Learn more
Google apps